FLUCORTAC (fludrocortisone), corticosteroid

Low clinical benefit for the treatment of neurogenic orthostatic hypotension, with no proven clinical added value for the treatment of this disease.

• FLUCORTAC has been granted a marketing authorisation for the treatment of neurogenic orthostatic hypotension in the event of failure of and to supplement non-medicinal measures.

• The data available, which have a low level of evidence, suggest a modest improvement in blood pressure on standing.

• No comparative data are available to date documenting the efficacy and safety of fludrocortisone compared to midodrine.

• The use of fludrocortisone is well-established in cases of failure of non-medicinal measures.